Syneos Health Appoints Colin Shannon as CEO
Exec joins the organization with decades of biopharma experience.
Syneos Health, a biopharma clinical and commercial solutions organization has appointed
Colin Shannon as CEO, effective immediately. He succeeds Michelle Keefe, who will continue her tenure with Syneos Health as a member of the executive leadership team. Shannon and Keefe will remain on the board of directors.
Shannon brings decades of leadership experience driving growth at global biopharmaceutical solutions organizations. During his 14 years at PRA Health Sciences, he served in executive roles, most recently as chairman and CEO. During his tenure, he led the company through a successful IPO and subsequent sale to ICON plc., where he also served on its board of directors.
"It is an honor to be tasked with leading Syneos Health at such an exciting time in its evolution,” comments Shannon. “I look forward to working with Michelle and the rest of the leadership team, the board ,and our dedicated employees as we push ourselves to new heights. Together, we will continue to deliver on our commitment to customers and strive to provide service that exceeds expectations."
Newron, Myung In Pharm Form Partnership Centered Around Treating Schizophrenia in South Korea
January 14th 2025The license agreement will feature an upcoming Phase III trial and—depending on results—the development, manufacturing, and commercialization of evenamide as a potential treatment option.
Machine Health in Pharmaceutical Production
December 2nd 2024Predictive maintenance in pharmaceutical production can help reduce downtime and increase efficiency. Grundfos Machine Health (GMH) uses artificial intelligence (AI)-driven wireless sensors to monitor motor health in real-time, identifying potential issues. This approach not only reduces maintenance costs but also ensures compliance with industry standards.
